KRONOS BIO INC. - COM

0,9500

29-ноября-24 12:45:00

15 мин. задержка

Акции

-0,0101

-1,05%

Сегодняшний диапазон

0,9353 - 1,0000

ISIN

N/A

Источник

NASDAQ

Kronos Bio Announces Appointment of Elizabeth Olek as Senior Vice President of Clinical Development

01 фев 2022 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia

06 дек 2021 06:00:01 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Positive Data from Ongoing Phase 1/2 Trial of Oral CDK9 Inhibitor KB-0742

29 ноя 2021 06:00:00 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in Upcoming Investor Conferences

24 ноя 2021 06:00:00 Источник Nasdaq GlobeNewswire
Kronos Bio Appoints Roshawn Blunt to Board of Directors

11 ноя 2021 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results

09 ноя 2021 15:10:42 Источник Nasdaq GlobeNewswire
Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus’ Platform

08 ноя 2021 15:44:44 Источник Nasdaq GlobeNewswire
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021

30 сен 2021 15:35:57 Источник Nasdaq GlobeNewswire
Kronos Bio Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations

14 сен 2021 07:00:02 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference

07 сен 2021 06:00:01 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and Second Quarter Financial Results

12 авг 2021 15:05:01 Источник Nasdaq GlobeNewswire
Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)

27 июл 2021 07:00:05 Источник Nasdaq GlobeNewswire
Kronos Bio to Highlight Progress Across Pipeline and Outline Growth Strategy at Virtual R&D Day Today

25 май 2021 07:00:03 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day

11 май 2021 15:05:01 Источник Nasdaq GlobeNewswire
Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference

06 май 2021 07:00:02 Источник Nasdaq GlobeNewswire
Kronos Bio Presents Preclinical Data for Oral CDK9 Inhibitor KB-0742 Demonstrating Sustained Inhibition of Tumor Growth in Multiple Cancers at AACR Annual Meeting 2021

10 апр 2021 07:30:00 Источник Nasdaq GlobeNewswire
Kronos Bio Comments on the Passing of Board Member John C. Martin, Ph.D.

31 мар 2021 10:25:04 Источник Nasdaq GlobeNewswire
Kronos Bio Appoints Taiyin Yang, Ph.D., to Board of Directors

26 мар 2021 07:00:00 Источник Nasdaq GlobeNewswire
Kronos Bio Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results

23 мар 2021 15:05:00 Источник Nasdaq GlobeNewswire
Kronos Bio to Present Pre-Clinical Data at the AACR Virtual Annual Meeting 2021 for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers

10 мар 2021 15:35:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
4
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.